Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan.
Bioorg Med Chem Lett. 2010 Jan 15;20(2):763-6. doi: 10.1016/j.bmcl.2009.11.018. Epub 2009 Nov 12.
Spirodiketopiperazine-based CCR5 antagonists, showing improved pharmacokinetic profiles without reduction in antagonist activity, were designed and synthesized. We also demonstrate the anti-HIV activity of a representative compound 12, as measured in a p24 assay.
基于螺环二酮哌嗪的 CCR5 拮抗剂,在不降低拮抗活性的情况下显示出改善的药代动力学特征,被设计和合成。我们还展示了代表性化合物 12 的抗 HIV 活性,该活性通过 p24 测定来衡量。